Huntington disease (Q56083219)

Europe PubMed Central

title

Huntington disease (English)

0 references

1 reference

3

James F. Gusella

0 references

Christopher A Ross

8

Christopher A. Ross

0 references

Blair R Leavitt

6

Blair R. Leavitt

0 references

Sarah J. Tabrizi

12

Sarah J. Tabrizi

0 references

Michael R. Hayden

4

Michael R. Hayden

0 references

Gillian Bates

1

Gillian P. Bates

0 references

E Ray Dorsey

2

Ray Dorsey

0 references

Ronald Wetzel

10

Ronald Wetzel

0 references

Chris Kay

5

Chris Kay

0 references

author name string

Martha Nance

7

0 references

Rachael I. Scahill

9

0 references

Edward J. Wild

Nature Reviews Disease Primers

11

0 references

publication date

23 April 2015

0 references

published in

0 references

page(s)

15005

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/nrdp.2015.5

0 references

cites work

Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Uptake of Huntington disease predictive testing in a complete population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Huntington disease: natural history, biomarkers and prospects for therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Prevalence estimates of Huntington disease in Caucasian populations are gross underestimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Incidence and mutation rates of Huntington's disease in Spain: experience of 9 years of direct genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Late-onset Huntington's disease: diagnostic and prognostic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

The CAG repeat at the Huntington disease gene in the Portuguese population: insights into its dynamics and to the origin of the mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

High frequency of intermediate alleles on Huntington disease-associated haplotypes in British Columbia's general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Factors associated with HD CAG repeat instability in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Genetic criteria for Huntington's disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Genetic modifiers of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Trinucleotide repeat length instability and age of onset in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Age, CAG repeat length, and clinical progression in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Association between Age and Striatal Volume Stratified by CAG Repeat Length in Prodromal Huntington Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Detection of Huntington's disease decades before diagnosis: the Predict-HD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

HEAT repeats in the Huntington's disease protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Polyglutamine expansion of huntingtin impairs its nuclear export

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

SUMO modification of Huntingtin and Huntington's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Slow amyloid nucleation via α-helix-rich oligomeric intermediates in short polyglutamine-containing huntingtin fragments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Membrane interactions of the amphipathic amino terminus of huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Huntingtin interacts with a family of WW domain proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

A two-step path to inclusion formation of huntingtin peptides revealed by number and brightness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Linear and extended: a common polyglutamine conformation recognized by the three antibodies MW1, 1C2 and 3B5H10

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

DNA instability in postmitotic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

MSH3 polymorphisms and protein levels affect CAG repeat instability in Huntington's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Mismatch repair genes Mlh1 and Mlh3 modify CAG instability in Huntington's disease mice: genome-wide and candidate approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Mutant huntingtin is present in neuronal grafts in Huntington disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Adapting proteostasis for disease intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Huntington's disease: underlying molecular mechanisms and emerging concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Converging pathways in the occurrence of endoplasmic reticulum (ER) stress in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Ubiquitin-proteasome system involvement in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Autophagy in Huntington disease and huntingtin in autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

What have we learned from gene expression profiles in Huntington's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

PGC-1α, mitochondrial dysfunction, and Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Unified Huntington's disease rating scale: Reliability and consistency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Diagnostic criteria for Huntington's disease based on natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Differential diagnosis of Huntington's disease: what the clinician should know

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Diagnostic genetic testing for Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Guidelines for the molecular genetics predictive test in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Experiences of predictive testing in young people at risk of Huntington's disease, familial cardiomyopathy or hereditary breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Providing predictive testing for Huntington disease via telehealth: results of a pilot study in British Columbia, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Reproductive options for prospective parents in families with Huntington's disease: clinical, psychological and ethical reflections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

The uptake and outcome of prenatal and pre-implantation genetic diagnosis for Huntington's disease in the Netherlands (1998-2008).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Evidence-based genetic counselling implications for Huntington disease intermediate allele predictive test results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

The association of CAG repeat length with clinical progression in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

CAG repeat number governs the development rate of pathology in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Randomized controlled clinical trial of "virtual house calls" for Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Predictors of neuropathological severity in 100 patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Interrater agreement in the assessment of motor manifestations of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Grasping premanifest Huntington's disease - shaping new endpoints for new trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Neurocognitive signs in prodromal Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Cognitive and functional decline in Huntington's disease: dementia criteria revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Episodic memory in dementia: Characteristics of new learning that differentiate Alzheimer's, Huntington's, and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

"Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

The cognitive burden in Huntington's disease: pathology, phenotype, and mechanisms of compensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Comprehensive care in Huntington's disease: a physician's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Huntington's disease: a caring approach to the end of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Chorea associated with Huntington's disease: to treat or not to treat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

An evidence-based approach in the treatment of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

A systematic review of the treatment studies in Huntington's disease since 1990.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Managing juvenile Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Promoting Excellence in End-of-Life Care: lessons learned from a cohort of nursing home residents with advanced Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Characteristics of individuals with Huntington disease in long-term care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Palliative care for people with late-stage Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Pharmacological management of Huntington's disease: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

The future of orphan drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Adverse childhood experiences of persons at risk for Huntington's disease or BRCA1/2 hereditary breast/ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Development of the HD-Teen Inventory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Living at risk: concealing risk and preserving hope in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

The Huntington's Disease health-related Quality of Life questionnaire (HDQoL): a disease-specific measure of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Validation of the first quality-of-life measurement for patients with Huntington's disease: the Huntington Quality of Life Instrument

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Predictors of nursing home placement in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Factors contributing to institutionalization in patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Thinking about the end of life: a common issue for patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Development of biomarkers for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Immune markers for Huntington's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

8OHdG is not a biomarker for Huntington disease state or progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Electrophysiological measures as potential biomarkers in Huntington's disease: review and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Stimulus-response compatibility in Huntington's disease: a cognitive-neurophysiological analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Alterations in voluntary movement execution in Huntington's disease are related to the dominant motor system: evidence from event-related potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Somatosensory evoked potentials correlate with genetics in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Brain networks in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Metabolic network as a progression biomarker of premanifest Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Microglial activation in presymptomatic Huntington's disease gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

White matter connectivity reflects clinical and cognitive status in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Complex brain networks: graph theoretical analysis of structural and functional systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Regulatory innovation and drug development for early-stage Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Prospects for neuroprotective therapies in prodromal Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

A polymorphic DNA marker genetically linked to Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Kinase inhibitors modulate huntingtin cell localization and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Suppression of protein aggregation by chaperone modification of high molecular weight complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Kynurenines in the CNS: recent advances and new questions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Targets for future clinical trials in Huntington's disease: what's in the pipeline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Evaluation of multi-modal, multi-site neuroimaging measures in Huntington's disease: Baseline results from the PADDINGTON study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Cellular inclusion bodies of mutant huntingtin exon 1 obscure small fibrillar aggregate species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Prion-like mechanisms in neurodegenerative diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

A novel mutation of NKX2-1 affecting 2 generations with hypothyroidism and choreoathetosis: part of the spectrum of brain-thyroid-lung syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Low utilization of prenatal and pre-implantation genetic diagnosis in Huntington disease - risk discounting in preventive genetics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Neuroprotection by GDNF-secreting stem cells in a Huntington's disease model: optical neuroimage tracking of brain-grafted cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Therapeutic Strategies for Huntington's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRDP.2015.5

0 references

Fatcat ID

release_qiv6jovkyvebrol5yrt6gmj7ny

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qiv6jovkyvebrol5yrt6gmj7ny